We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ALACT market cap is 3.94M. The company's latest EPS is EUR -1.1831 and P/E is -0.21.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 1.57M | 1.48M | 3M | 2.7M | 2.63M |
| Operating Income | -5.17M | -7.58M | -11.89M | -15.12M | -17.57M |
| Net Income | -5.05M | -7.65M | -12.61M | -15.88M | -18.64M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 15.4M | 11.02M | 17.88M | 12.94M | 9.72M |
| Total Liabilities | 6.37M | 9.3M | 6.86M | 15.19M | 15.03M |
| Total Equity | 9.03M | 1.72M | 11.02M | -2.24M | -5.31M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -4.28M | -6.74M | -13.75M | -12.1M | -13.02M |
| Investing | 326k | -53k | -12k | -66k | -46k |
| Financing | 6.64M | 1.5M | 17.52M | 7.42M | 10.36M |
| Market Cap | 3.94M |
| Price to Earnings Ratio | -0.21 |
| Price to Sales Ratio | 1.5 |
| Price to Cash Ratio | 1.01 |
| Price to Book Ratio | -0.74 |
| Dividend Yield | - |
| Shares Outstanding | 15.76M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 4.33k |
| 52 Week Change | -91.53% |
| 52 Week High | 5.32 |
| 52 Week Low | 0.22 |
| Spread (Intraday) | -0.02 (-6.67%) |
| Company Name | Acticor Biotech |
| Address |
wojo building 82 avenue du maine paris, paris 75014 |
| Website | https://www.acticor-biotech.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
